Clinical trials: Aggressive Behaviour
Lymphoma, Non-Hodgkin's
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
- Trial name
- NCT00413036
- Testing
- lenalidomide
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 217 people
- Sponsor
- Celgene
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Prostate Cancer Metastatic
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
It is a Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer.
- Trial name
- PEAPOD_FOS (NCT05563558)
- Testing
- Pembrolizumab, Carboplatin, Cabazitaxel
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Fundacion Oncosur
Non-small Cell Lung Cancer, Spread Through Air Space
Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting aggressive histological pattern in resected non-small cell lung cancer based on a multicenter prospective cohort.
- Conditions
- Non-small Cell Lung Cancer, Spread Through Air Space, Visceral Pleural Invasion, Lymphovascular Invasion
- Trial name
- NCT05925738
- Testing
- PET/CT-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Oppositional Defiant Disorder
Treatment of Children With Peer Related Aggressive Behavior
The efficacy of the Treatment Program for Children with Aggressive Behaviour (Therapieprogramm für Kinder mit aggressivem Verhalten, THAV) which is a social competence training delivered in an individual format will be evaluated…
- Trial name
- NCT01406067
- Testing
- Treatment Program for Children with Aggressive Behavior, Play group
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Cologne
Chronic Periodontal Disease, Aggressive Periodontitis
Transplantation of Bone Marrow Mesenchymal Stromal Cells for Periodontal Regeneration
The goal of this study is to evaluate the capacity of allogeneic bone marrow mesenchymal stromal cells (MSC) to induce bone regeneration in patients with periodontal disease.
- Trial name
- BMMSC (NCT05975892)
- Testing
- Transplantation of allogeneic MSCs in periodontal disease
- Where
- Venezuela
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Instituto Venezolano de Investigaciones Cientificas
Lymphoma
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00069966
- Testing
- filgrastim, rituximab, cisplatin
- Where
- 29 sites in United States, Puerto Rico
- Sponsor
- Theradex
Workplace Violence, Health Professionals
Chatbot to Support Healthcare Professionals Experiencing Workplace Aggression
This study aims to design, develop, and validate a chatbot (SANIDAD SEGURA) intended to support healthcare professionals who experience workplace aggression.
- Conditions
- Workplace Violence, Health Professionals, Chatbot, Digital Health
- Trial name
- Sanidad-Segura (NCT07473531)
- Testing
- Chatbot SANIDAD SEGURA
- Where
- Spain
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Distrito Sanitario Almeria
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
- Trial name
- NCT00807495
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphocytic, Lymphoma
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
- Trial name
- NCT00035022
- Testing
- BCX-1777
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- BioCryst Pharmaceuticals
Aggression
Effect of Aggression Management Care Bundle
The aim of this sequential randomized controlled experimental design study is to develop an aggression care bundle approach in psychiatric care for patients with psychotic disorders, to use it in a psychiatric clinic, and to…
- Trial name
- NCT06661824
- Testing
- Aggression management care bundle
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Abant Izzet Baysal University
Lymphoblastic Lymphoma
ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors
ATG based conditioning regimen in HLA related allogeneic hematopoietic stem cell transplantation for aggressive T-cell tumors: multi-center, open, randomized controlled clinical study
- Trial name
- NCT02938741
- Testing
- Anti-human Thymoglobulin
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
DLBCL
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
Diffuse Large B-cell Lymphoma (DLBCL) is the most frequent high grade lymphoma in adults. Although immunotherapy has improved its prognosis, DLBCL is a heterogeneous disease with patients exhibiting a wide range of outcomes with…
- Trial name
- BMS-LyTrans (NCT01287923)
- Where
- 17 sites in France
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
End of Life Care, Violent Aggressive Behavior
Death, Dying, Violence and Aggression as Shown on Medical Television Series.
Medical TV dramas have become very popular in recent years. These shows are mainly created for entertainment and often do not reflect what really happens in hospitals.
- Conditions
- End of Life Care, Violent Aggressive Behavior, Television Viewing, Media Use
- Trial name
- NCT07416669
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 500 people
- Sponsor
- King's College Hospital NHS Trust
Transgenderism
Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC
The aim of this study is to investigate transgender men and non-binary persons before and during testosterone treatment. The study will focus on: Cardiovascular status Muscle strenght and power Aggression and quality of life…
- Trial name
- NCT04254354
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Marianne Andersen
Problem Drinking, Aggression
Feasibility and Acceptability of Mindfulness-based Resilience Training for Rural Law Enforcement Officers
Rural law enforcement officers (LEOs) are exposed to unique and significant stressors, yet have access to fewer resources, compared to urban counterparts, to mitigate harmful effects of stress.
- Conditions
- Problem Drinking, Aggression, Stress, Psychological
- Trial name
- NCT05629637
- Testing
- Mindfulness-Based Resilience Training (MBRT)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pacific University
Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who…
- Trial name
- NCT06915766
- Testing
- Bezuclastinib
- Where
- 23 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
This phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Trial name
- NCT03749018
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Bond, MD